Search Within

Isabelle C Riviere

  1. "Jae Park"
  2. "Terence Purdon"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (4)
Groups
  1. Adult Leukemia (26)
  2. Center for Hematologic Malignancies (26)
  3. Department of Medicine (26)
  4. GSK Faculty (26)
  5. Hematologic Malignancies Research (26)
  6. Hematologic Malignancies, Division of (26)

More Groups

People
  1. Jae Park (26)
  2. Terence Purdon (26)
  3. Renier Brentjens (25)
  4. Michel Sadelain (22)
  5. Xiuyan Wang (21)
  6. Brigitte Senechal (15)

More People

Years
  1. 2022 (1)
  2. 2021 (3)
  3. 2019 (2)
  4. 2018 (4)
  5. 2017 (5)
  6. 2016 (4)

More Years

Publications
  1. Blood (9)
  2. Journal of Clinical Oncology (6)
  3. Cytotherapy (2)
  4. Haematologica (2)
  5. Bone Marrow Transplantation (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Hematology (9)
  2. American Society of Clinical Oncology (6)
  3. Elsevier Science Ltd. (2)
  4. Ferrata Storti Foundation (2)
  5. Nature Publishing Group (2)
  6. Amer Soc Clinical Investigation Inc (1)

More Publishers

Results (26)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells
    Meeting Abstract

    Santomasso, B.; Park, J. H.; Riviere, I.; Mead, E.; Halton, E.; Diamonte, C.; Purdon, T.; Senechal, B.; Li, D.; Sadelain, M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Santomasso, B.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T.; Wang, Y.; Halton, E.; Diamonte, C.; Li, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Durable long-term survival of adult patients with B-ALL after CD19 CAR (19-28z) T cell therapy
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Purdon, T.; Brentjens, R.; Sadelain, M.
    Haematologica (2017)

    Fulltext@MSK | Save
  • A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Updated results: Phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save
  • Phase I trial: CD19-targeted CAR T-cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M.; Park, J.; RivieĢ€re, I.; Senechal, B.; Hsu, M.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save